Data as of Mar 06
| -1.75 / -6.58%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 55.00, with a high estimate of 70.00 and a low estimate of 44.00. The median estimate represents a +121.24% increase from the last price of 24.86.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.